Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 18:19:2.
doi: 10.1186/s12907-019-0084-9. eCollection 2019.

Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays

Christina D Martinez-Brokaw  1   2 , Joshua B Radke  3 , Joshua G Pierce  1   2 , Alexandra Ehlers  4 , Sean Ekins  5 , Kelly E Wood  6 , Jon Maakestad  4 , Jacqueline A Rymer  7 , Kenichi Tamama  7   8   9   10 , Matthew D Krasowski  4
Affiliations

Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays

Christina D Martinez-Brokaw et al. BMC Clin Pathol. .

Abstract

Background: Vilazodone is an FDA approved medication used to treat major depressive disorder. The authors describe two cases of accidental vilazodone exposure in toddlers who presented with symptoms similar to amphetamine exposure and also with unexplained positive amphetamine urine immunoassay drug screens. Given a lack of published data on cross-reactivity of vilazodone and its metabolites with drug of abuse screening tests, the authors investigated drug of abuse immunoassay cross-reactivity of vilazodone and metabolites using computational and empirical approaches.

Methods: To ascertain the likelihood that vilazodone would cross-react with drug of abuse screening immunoassays, the authors assessed the two-dimensional (2D) similarity of the vilazodone parent molecule and known metabolites to an array of antigenic targets for urine immunoassay drug screens. To facilitate studies of the commercially unavailable M17 metabolite, it was prepared synthetically through a novel scheme. Urine and serum were spiked with vilazodone and M17 into urine (200-100,000 ng/mL) and serum (20-2000 ng/mL) samples and tested for cross-reactivity.

Results: Computational analysis using 2D similarity showed that vilazodone and metabolites have generally low similarity to antigenic targets of common drug of abuse screening immunoassays, predicting weak or no cross-reactivity. The M17 metabolite had 2D similarity to amphetamines and tricyclic antidepressants in a range similar to some other compounds exhibiting weak cross-reactivity on these immunoassays. Cross-reactivity testing was therefore performed on two different urine amphetamines immunoassays and a serum tricyclic antidepressant immunoassay. However, actual testing of cross reactivity for vilazodone and the M17 metabolite did not detect cross-reactivity for any urine amphetamines screen at concentrations up to 100,000 ng/mL and for a serum tricyclic antidepressants assays at concentrations up to 2000 ng/mL.

Conclusion: While the vilazodone metabolite M17 has weak 2D structural similarity to amphetamines and tricyclic antidepressants, the current study did not demonstrate any experimental cross-reactivity with two different urine amphetamines immunoassays and a serum tricyclic antidepressant immunoassay. Vilazodone ingestions in young children present a diagnostic challenge in their similarity to amphetamine ingestions and the lack of routine laboratory tests for vilazodone. Further work is needed to understand the metabolic profile for vilazodone in children versus adults.

Keywords: Amphetamines; False positive reactions; Immunoassay; Similarity; Toxicology.

PubMed Disclaimer

Conflict of interest statement

This study had approval from the University of Iowa Institutional Review Board as a retrospective study (protocol #201705809).Not applicable.The authors all declare no conflicts of interest apart from SE who is the Chief Executive Officers of Collaborations Pharmaceuticals, Inc.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Metabolic Pathways of Vilazodone. Information compiled from multiple sources [, –15]
Fig. 2
Fig. 2
Chemical Synthetic Scheme for the M17 Metabolite of Vilazodone
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Frampton JE. Vilazodone: in major depressive disorder. CNS Drugs. 2011;25(7):615–627. doi: 10.2165/11207550-000000000-00000. - DOI - PubMed
    1. Hellerstein DJ, Flaxer J. Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy. Core Evid. 2015;10:49–62. doi: 10.2147/CE.S54075. - DOI - PMC - PubMed
    1. Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. A review of current evidence for vilazodone in major depressive disorder. Int J Psychiatry Clin Pract. 2013;17(3):160–169. doi: 10.3109/13651501.2013.794245. - DOI - PubMed
    1. Boinpally R, Gad N, Gupta S, Periclou A. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects. Clin Ther. 2014;36(11):1638–1649. doi: 10.1016/j.clinthera.2014.08.003. - DOI - PubMed
    1. Acker EC, Sinclair EA, Beardsley AL, Ahmed SS, Froberg BA. Acute Vilazodone toxicity in a pediatric patient. J Emerg Med. 2015;49(3):284–286. doi: 10.1016/j.jemermed.2015.04.032. - DOI - PubMed

LinkOut - more resources